Alzforum’s coverage of the 2021 International Conference on Frontotemporal Dementia concludes with an update on FTD clinical trials.  

Ifølge det final artikel in the series, trials for carriers of GRN mutations are the farthest along in clinical trial developments. Julio Rojas of the University of California, San Francjegsco, said during the conference that “it’s likely we’ll see a treatment for GRN mutation carriers with FTD before we see one for [Alzheimer’s].” 

Companies such as Prevail Therapeutics and Passage Bio are currently looking into trials focused on -en gene-therapy approach. Currently, FTD trials have been limited to carriers of pathogenic C9orf72, GRN, eller KORT mutations and individuals diagnosed with lidelser such as progressive supranuclear palsy.  

Read more about the status of FTD clinical trials in the full Alzforum article her.  

International Society for Frontotemporal Dementias indkaldte nærmest 12th International konference om FTD 3-5 marts. Read Alzforums seven-part conference coverage series her.  

Yderligere afleveringer i serien kan findes her:

Del et

Anden del

Tredje del

Del fire

Femte del

Del seks